In a ceremony yesterday, company officials dedicated a 225,000-sf bioproducts pilot manufacturing plant that will be used to produce drugs on a small scale for clinical trials. The facility was designed to allow Lily to operate up to one-half of the manufacturing capacity required for full-scale manufacturing. According to Lily, this approach will help ease the transition from development to full-scale manufacturing.
A 100,000-sf research support facility also was dedicated yesterday. Nearly 700 scientist, engineers and support staff will relocate to the facility.
Construction of a 475,000-sf bioproducts research and development laboratory is scheduled for completion in the first quarter of 2007.The facility will be used by Lily scientists to conduct research in molecular and cell biology, analytical science, pharmaceutics and engineering.
The construction of the three buildings and Lily's acquisition in 2004 of Applied Molecular Evolution, a San Diego-based operation that conducts protein optimization research, accounts for a total biotech capital investment of approximately $1 billion.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
